A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This study is looking at a new gene therapy, SGT-501, for people with a heart condition called Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT can cause dangerous fast heartbeats. This is a very early study (Phase 1) to see if SGT-501 is safe and tolerable for people. Researchers will also be trying to find the right amount (dose) of the treatment to give. The study will start with adults (18 years and older). If things go well, younger people aged 7 to under 18 might be included later. Everyone in the study will get a single dose of SGT-501 and will be carefully monitored by doctors for five years to check their health.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This research is looking into a new treatment called SGT-501 for a specific heart condition known as Catecholaminergic Polymorphic Ventricular Tachycardia, or CPVT. CPVT is a rare condition that can cause your heart to beat very fast and irregularly, especially during exercise or stress. These fast heartbeats can be dangerous.
The SGT-501 treatment is a type of gene therapy. This means it aims to correct the underlying genetic problem that causes CPVT. This is a very early stage of research, called a Phase 1 study. Its main goal is to find out if the treatment is safe for people and what the best amount (dose) to give is. It's the first time SGT-501 is being tested in humans, so safety is the top priority.
Initially, the study will involve adults aged 18 and over. If the results show that it is safe, doctors might then include young people aged between 7 and 18. Each person will receive one dose of SGT-501, and their health will be carefully watched for a total of five years to understand the long-term effects of the treatment.
النقاط الرئيسية
- This is an early study of a new gene therapy for CPVT.
- The main goal is to check the safety of the treatment (SGT-501) and find the right dose.
- Initially, only adults with CPVT can join, with potential for younger participants later.
- Participants will be closely monitored for five years after receiving a single treatment.
- Taking part helps advance medical knowledge, but personal benefits are not guaranteed.
من قد يكون مؤهلاً؟
To join this study, you must have a clear diagnosis of CPVT, meaning you've had dangerous fast heartbeats during exercise or similar problems. Your doctors will also need to confirm that your CPVT is caused by a specific genetic change (called a RYR2 variant).
It's important that you've had serious heart events in the past, such as a collapsed because of your heart, or required an electric shock from a device (ICD) to correct your heartbeat. You must also be on a stable dose of your current heart medication (like beta-blockers or flecainide) for at least a month.
There are also some health conditions that would prevent you from joining. For example, if you have certain liver or kidney problems, or issues with your blood clotting. You'll also need to be up-to-date with your meningitis vaccination or be willing to get it.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Do I have a confirmed diagnosis of CPVT?
- Have I had a serious heart event (like collapsing or needing an ICD shock)?
- Am I 18 years old or older (or between 7 and 18 if the study expands)?
- Am I currently on a stable dose of my CPVT medication?
- Do I have any serious problems with my liver, kidneys, or blood clotting?
- Am I up-to-date with my meningitis vaccination, or willing to get it?
ماذا يتضمن المشاركة؟
If you join this study, you would receive a single dose of the SGT-501 gene therapy given directly into your vein. Doctors will then carefully monitor your health for a long time. The first year is considered the active treatment period, where you'll have more regular check-ups. After that, monitoring will continue for another four years, totalling five years of follow-up care to see how you are doing in the long term. This will involve regular visits to the clinic for tests and examinations.
المخاطر والفوائد المحتملة
المواقع (5)
- مستشفى بوسطن للأطفالالرمز البريدي المؤكدبوسطن، الولايات المتحدة· التوظيف
- عيادة مايوالرمز البريدي المؤكدروتشستر، الولايات المتحدة· التوظيف
- عيادة كليفلاندالرمز البريدي المؤكدكليفلاند، الولايات المتحدة· التوظيف
- جامعة بنسلفانياالرمز البريدي المؤكدفيلادلفيا، الولايات المتحدة· لم يبدأ التوظيف بعد
- مستشفى سانت بولالرمز البريدي المؤكدفانكوفر، كندا· التوظيف
أسئلة شائعة
What is CPVT?
CPVT is a rare heart condition that can cause dangerous, fast heartbeats, especially during exercise or stress.
What is SGT-501?
SGT-501 is a new type of gene therapy being tested to see if it can help correct the genetic problem that causes CPVT.
من يمكنه المشاركة في هذه الدراسة؟
Initially, adults aged 18 and over with a clear diagnosis of CPVT and a history of serious heart events can join. Younger people might be included later.
How long will I be monitored?
You will be carefully watched by doctors for a total of five years after receiving the treatment.
Is this treatment guaranteed to work?
No, this is an early-stage study, and there's no guarantee the treatment will work. The main goal is to check its safety and find the right amount to give.
كيفية معرفة المزيد
Solid Bio Clinical Trials
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.